Skip to main content

Sitagliptin Disease Interactions

There are 2 disease interactions with sitagliptin.

Major

DPP-4 inhibitors (applies to sitagliptin) pancreatitis

Major Potential Hazard, Low plausibility.

There have been postmarketing reports of acute pancreatitis in patients taking DPP-4 inhibitors. These drugs should be used with caution in patients with a history of pancreatitis or pancreatic disease, although it is unknown if they are at increased risk. Patients should be observed for signs and symptoms of pancreatitis during treatment. If pancreatitis is suspected, treatment should be discontinued immediately and appropriate management should be initiated.

References

  1. "Product Information. Januvia (sitagliptin)." Merck & Company Inc (2006):
  2. "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb (2009):
  3. "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim (2011):
  4. "Product Information. Nesina (alogliptin)." Takeda Pharmaceuticals America (2013):
View all 4 references
Moderate

DPP-4 (applies to sitagliptin) renal dysfunction

Moderate Potential Hazard, High plausibility.

It is recommended to assess renal function prior to initiating treatment with DPP-4 inhibitors. Patients with moderate to severe renal insufficiency and end stage renal dysfunction will require a dose adjustment. Linagliptin will not require a dose adjustment per manufacturer's information. Additionally, there have been postmarketing reports of worsening renal function in some patients with renal insufficiency taking sitagliptin at inappropriate doses. However, sitagliptin has not been found to be nephrotoxic in preclinical studies or clinical trials at appropriate doses.

References

  1. "Product Information. Januvia (sitagliptin)." Merck & Company Inc (2006):
  2. "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb (2009):
  3. "Product Information. Tradjenta (linagliptin)." Boehringer Ingelheim (2011):
  4. "Product Information. Nesina (alogliptin)." Takeda Pharmaceuticals America (2013):
View all 4 references

Sitagliptin drug interactions

There are 278 drug interactions with sitagliptin.

Sitagliptin alcohol/food interactions

There is 1 alcohol/food interaction with sitagliptin.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.